

Agnieszka Anna Kaczor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1763288/publications.pdf>

Version: 2024-02-01

111
papers

1,785
citations

331670

21
h-index

361022

35
g-index

113
all docs

113
docs citations

113
times ranked

2162
citing authors

#	ARTICLE	IF	CITATIONS
1	Allosteric modulation of dopamine D2L receptor in complex with Gi1 and Gi2 proteins: the effect of subtle structural and stereochemical ligand modifications. <i>Pharmacological Reports</i> , 2022, 74, 406-424.	3.3	5
2	The Role of Lipids in Allosteric Modulation of Dopamine D2 Receptorâ€”In Silico Study. <i>Molecules</i> , 2022, 27, 1335.	3.8	5
3	WaterMapâ€”Guided Structureâ€”Based Virtual Screening for Acetylcholinesterase Inhibitors. <i>ChemMedChem</i> , 2022, 17, .	3.2	5
4	Screening and Structureâ€”Activity Relationship of D2AAK1 Derivatives for Potential Application in the Treatment of Neurodegenerative Diseases. <i>Molecules</i> , 2022, 27, 2239.	3.8	1
5	In vitro and in vivo evaluation of antioxidant and neuroprotective properties of antipsychotic D2AAK1. <i>Neurochemical Research</i> , 2022, 47, 1778-1789.	3.3	2
6	Overcoming Depression with 5-HT2A Receptor Ligands. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10.	4.1	19
7	Experimental and Computational Structural Studies of 2,3,5-Trisubstituted and 1,2,3,5-Tetrasubstituted Indoles as Non-Competitive Antagonists of GluK1/GluK2 Receptors. <i>Molecules</i> , 2022, 27, 2479.	3.8	3
8	What are the challenges with multi-targeted drug design for complex diseases?. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 673-683.	5.0	14
9	Multitarget Derivatives of D2AAK1 as Potential Antipsychotics: The Effect of Substitution in the Indole Moiety. <i>ChemMedChem</i> , 2022, 17, .	3.2	5
10	Multi-targeted drug design strategies for the treatment of schizophrenia. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 101-114.	5.0	10
11	5-Methoxy-1-methyl-2-[[4-(2-hydroxyphenyl)piperazin-1-yl]methyl]-1Hindole (KAD22) with Antioxidant Activity. <i>Letters in Organic Chemistry</i> , 2021, 18, .	0.5	0
12	Synthesis, docking studies, and pharmacological evaluation of 2â€”hydroxypropylâ€”4â€”aryl piperazine derivatives as serotonergic ligands. <i>Archiv Der Pharmazie</i> , 2021, 354, 2000414.	4.1	7
13	Some Dietary Phenolic Compounds Can Activate Thyroid Peroxidase and Inhibit Lipoxigenase-Preliminary Study in the Model Systems. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5108.	4.1	8
14	Docking-Based 3D-QSAR Studies for 1,3,4-oxadiazol-2-one Derivatives as FAAH Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6108.	4.1	9
15	N-(3-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}propyl)-1H-indazole-3-carboxamide (D2AAK3) as a potential antipsychotic: In vitro, in silico and in vivo evaluation of a multi-target ligand. <i>Neurochemistry International</i> , 2021, 146, 105016.	3.8	10
16	Current Approaches and Tools Used in Drug Development against Parkinsonâ€™s Disease. <i>Biomolecules</i> , 2021, 11, 897.	4.0	11
17	Experimental and computational structural studies of 5-substituted-3-(1-arylmethyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles. <i>Journal of Molecular Structure</i> , 2021, 1245, 130998.	3.6	2
18	Role of N_C-terminus in function and dynamics of sirtuin 7: an in silico study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 38, 1283-1291.	3.5	7

#	ARTICLE	IF	CITATIONS
19	The Antipsychotic D2AAK1 as a Memory Enhancer for Treatment of Mental and Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8849.	4.1	4
20	Novel Positive Allosteric Modulators of μ Opioid Receptor—Insight from In Silico and In Vivo Studies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8463.	4.1	9
21	N-(2-Hydroxyphenyl)-1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidine-4-Carboxamide (D2AAK4), a Multi-Target Ligand of Aminergic GPCRs, as a Potential Antipsychotic. <i>Biomolecules</i> , 2020, 10, 349.	4.0	14
22	2,4-Dichlorophenoxyacetic Thiosemicarbazides as a New Class of Compounds against Stomach Cancer Potentially Intercalating with DNA. <i>Biomolecules</i> , 2020, 10, 296.	4.0	13
23	Preferential Coupling of Dopamine D2S and D2L Receptor Isoforms with Gi1 and Gi2 Proteins—In Silico Study. <i>International Journal of Molecular Sciences</i> , 2020, 21, 436.	4.1	14
24	In Vitro and In Vivo Models for the Investigation of Potential Drugs Against Schizophrenia. <i>Biomolecules</i> , 2020, 10, 160.	4.0	15
25	1,2,4-Triazolin-5-thione derivatives with anticancer activity as CK1 β kinase inhibitors. <i>Bioorganic Chemistry</i> , 2020, 99, 103806.	4.1	13
26	Tuning Down the Pain — An Overview of Allosteric Modulation of Opioid Receptors: Mechanisms of Modulation, Allosteric Sites, Modulator Syntheses. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 2852-2865.	2.1	5
27	Thyroid Peroxidase Activity is Inhibited by Phenolic Compounds—Impact of Interaction. <i>Molecules</i> , 2019, 24, 2766.	3.8	18
28	Synthesis, pharmacological and structural studies of 5-substituted-3-(1-arylmethyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as multi-target ligands of aminergic GPCRs. <i>European Journal of Medicinal Chemistry</i> , 2019, 180, 673-689.	5.5	19
29	The Universal 3D QSAR Model for Dopamine D2 Receptor Antagonists. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4555.	4.1	6
30	Synthesis, docking studies, and pharmacological evaluation of 5HT _{2C} ligands containing the <i>N</i> -cyanoisonicotinamide or <i>N</i> -cyanopicolinamide nucleus. <i>Archiv Der Pharmazie</i> , 2019, 352, e1800373.	4.1	7
31	Molecular mechanisms of allosteric probe dependence in μ opioid receptor. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 36-47.	3.5	12
32	Molecular interactions of type I and type II positive allosteric modulators with the human $\alpha 7$ nicotinic acetylcholine receptor: an <i>in silico</i> study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 411-439.	3.5	12
33	Comparative molecular field analysis and molecular dynamics studies of the dopamine D2 receptor antagonists without a protonatable nitrogen atom. <i>Medicinal Chemistry Research</i> , 2018, 27, 1149-1166.	2.4	7
34	Protein—Protein Docking in Drug Design and Discovery. <i>Methods in Molecular Biology</i> , 2018, 1762, 285-305.	0.9	17
35	Thermal and spectroscopic studies of 2,3,5-trisubstituted and 1,2,3,5-tetrasubstituted indoles as non-competitive antagonists of GluK1/GluK2 receptors. <i>Journal of Thermal Analysis and Calorimetry</i> , 2018, 133, 935-944.	3.6	9
36	Opportunities and Challenges in the Discovery of Allosteric Modulators of GPCRs. <i>Methods in Molecular Biology</i> , 2018, 1705, 297-319.	0.9	16

#	ARTICLE	IF	CITATIONS
37	Challenges and Opportunities in Drug Discovery of Biased Ligands. <i>Methods in Molecular Biology</i> , 2018, 1705, 321-334.	0.9	6
38	Synthesis, crystal structure, thermal, spectroscopic and theoretical studies of N3O2-donor Schiff base and its complex with CuII ions. <i>Polyhedron</i> , 2018, 139, 271-281.	2.2	11
39	Multi-Target Approach for Drug Discovery against Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3105.	4.1	66
40	Synthesis, Structural and Thermal Studies of 3-(1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)-5-ethoxy-1H-indole (D2AAK1_3) as Dopamine D2 Receptor Ligand. <i>Molecules</i> , 2018, 23, 2249.	3.8	11
41	Do new N-substituted 3-amino-4-phenyl-5-oxo-pyrazolinecarboxamide derivatives exhibit antitubercular potential?. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 121, 155-165.	4.0	1
42	Current Concepts and Treatments of Schizophrenia. <i>Molecules</i> , 2018, 23, 2087.	3.8	284
43	Synthesis, Experimental and Computational Studies of N-(4-amino-6-oxo-1,6-dihydro-2H-pyridin-2-yl)ethan-1-amine (1,6-dihydro-2H-pyridin-2-yl)ethan-1-amine). <i>Molecules</i> , 2018, 23, 2249.	0.5	2
44	Inhibitory Effects of 1,4-disubstituted Thiosemicarbazide Derivatives on <i>Streptococcus mutans</i> and <i>Streptococcus sanguinis</i> Mono-species Biofilms. <i>Letters in Drug Design and Discovery</i> , 2018, 15, 843-850.	0.7	1
45	Novel thiosemicarbazide derivatives with 4-nitrophenyl group as multi-target drugs: Î±-glucosidase inhibitors with antibacterial and antiproliferative activity. <i>Biomedicine and Pharmacotherapy</i> , 2017, 93, 1269-1276.	5.6	25
46	Recent Advances and Applications of Molecular Docking to G Protein-Coupled Receptors. <i>Molecules</i> , 2017, 22, 340.	3.8	51
47	Signaling within Allosteric Machines: Signal Transmission Pathways Inside G Protein-Coupled Receptors. <i>Molecules</i> , 2017, 22, 1188.	3.8	11
48	Novel Antibacterial Compounds and their Drug Targets - Successes and Challenges. <i>Current Medicinal Chemistry</i> , 2017, 24, 1948-1982.	2.4	31
49	Computational methods for studying G protein-coupled receptors (GPCRs). <i>Methods in Cell Biology</i> , 2016, 132, 359-399.	1.1	31
50	Fragmental Method KowWIN as the Powerful Tool for Prediction of Chromatographic Behavior of Novel Bioactive Urea Derivatives. <i>Journal of the Brazilian Chemical Society</i> , 2016, , .	0.6	1
51	Synthesis and Pharmacological Evaluation of Novel 1-(1,4-Alkylaryl-disubstituted-4,5-dihydro-1H-imidazo)-3-substituted Urea Derivatives. <i>Molecules</i> , 2016, 21, 582.	3.8	1
52	Structure-Based Virtual Screening for Dopamine D ₂ Receptor Ligands as Potential Antipsychotics. <i>ChemMedChem</i> , 2016, 11, 718-729.	3.2	51
53	<i>In silico</i> Exploration of the Conformational Universe of GPCRs. <i>Molecular Informatics</i> , 2016, 35, 227-237.	2.5	7
54	The Pseudo-Michael Reaction of 2-Hydrazinylidene-1-Arylimidazolidines with Diethyl Ethoxymethylenemalonate. <i>Journal of Heterocyclic Chemistry</i> , 2016, 53, 571-578.	2.6	0

#	ARTICLE	IF	CITATIONS
55	The dopamine D2 receptor dimer and its interaction with homobivalent antagonists: homology modeling, docking and molecular dynamics. <i>Journal of Molecular Modeling</i> , 2016, 22, 203.	1.8	28
56	Positive allosteric modulators of $\alpha 7$ nicotinic acetylcholine receptors affect neither the function of other ligand- and voltage-gated ion channels and acetylcholinesterase, nor $\beta 2$ -amyloid content. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 76, 19-30.	2.8	10
57	Potent and selective N-(4-sulfamoylphenyl)thiourea-based GPR55 agonists. <i>European Journal of Medicinal Chemistry</i> , 2016, 107, 119-132.	5.5	18
58	Interplay between Two Allosteric Sites and Their Influence on Agonist Binding in Human μ Opioid Receptor. <i>Journal of Chemical Information and Modeling</i> , 2016, 56, 563-570.	5.4	35
59	In vitro, molecular modeling and behavioral studies of 3-[[4-(5-methoxy-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl]-1,2-dihydroquinolin-2-one (D2AAK1) as a potential antipsychotic. <i>Neurochemistry International</i> , 2016, 96, 84-99.	3.8	35
60	Discovery of nitroaryl urea derivatives with antiproliferative properties. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 608-618.	5.2	13
61	Synthesis and structure of new 1-cyanoacetyl-4-arylsemicarbazide derivatives with potential anticancer activity. <i>Journal of Molecular Structure</i> , 2016, 1104, 24-32.	3.6	6
62	Synthesis, antiviral activity and structure-activity relationship of 1-(1-aryl-4,5-dihydro-1H-imidazolo[4,5-d]imidazole)-3-chlorosulfonylureas and products of their cyclization. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 787-795.	5.2	2
63	Synthesis, Central Nervous System Activity and Structure-Activity Relationships of Novel 1-(1-Alkyl-4-aryl-4,5-dihydro-1H-imidazo)-3-substituted Urea Derivatives. <i>Molecules</i> , 2015, 20, 3821-3840.	3.8	6
64	Synthesis, Structural Studies and Molecular Modelling of a Novel Imidazoline Derivative with Antifungal Activity. <i>Molecules</i> , 2015, 20, 14761-14776.	3.8	9
65	Synthesis, central nervous system activity and structure-activity relationship of N-substituted derivatives of 1-arylimidazolidin-2-ylideneurea and products of their cyclization. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2015, 30, 746-760.	5.2	8
66	Pharmacological and molecular studies on the interaction of varenicline with different nicotinic acetylcholine receptor subtypes. Potential mechanism underlying partial agonism at human $\alpha 2$ and $\alpha 4$ subtypes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2015, 1848, 731-741.	2.6	21
67	Synthesis and molecular docking of novel non-competitive antagonists of GluK2 receptor. <i>Medicinal Chemistry Research</i> , 2015, 24, 810-817.	2.4	2
68	Multi-Component Protein - Protein Docking Based Protocol with External Scoring for Modeling Dimers of G Protein-Coupled Receptors. <i>Molecular Informatics</i> , 2015, 34, 246-255.	2.5	15
69	Synthesis and antiviral activity of 1-(1,3-disubstitutedimidazolidin-2-ylidene)-3-ethoxycarbonylmethylurea derivatives. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2015, 31, 1-8.	5.2	2
70	Revisiting 1,3,4-Oxadiazol-2-ones: Utilization in the Development of ABHD6 Inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6335-6345.	3.0	10
71	Activation and Allosteric Modulation of Human μ Opioid Receptor in Molecular Dynamics. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 2421-2434.	5.4	31
72	The formation of a neutral manganese(III) complex containing a tetradentate Schiff base and a ketone - synthesis and characterization. <i>Journal of Coordination Chemistry</i> , 2015, 68, 3701-3717.	2.2	23

#	ARTICLE	IF	CITATIONS
73	Comparative molecular field analysis and molecular dynamics studies of $\hat{1}\pm/\hat{1}^2$ hydrolase domain containing 6 (ABHD6) inhibitors. <i>Journal of Molecular Modeling</i> , 2015, 21, 250.	1.8	29
74	Optimization of 1,2,5- $\hat{1}$ Thiadiazole Carbamates as Potent and Selective ABHD6 Inhibitors. <i>ChemMedChem</i> , 2015, 10, 253-265.	3.2	29
75	From Synthesis and Spectral Analysis to Molecular Modeling – Multidimensional Teaching of Medicinal Chemistry: Aspirin as an Example. <i>Indian Journal of Pharmaceutical Education and Research</i> , 2015, 49, 82-87.	0.6	1
76	Structural Studies on N-(1-naphthyl)-3-amino-5-oxo-4-phenyl-1H-pyrazole-1-carboxamide with Antibacterial Activity. <i>Letters in Organic Chemistry</i> , 2014, 11, 40-48.	0.5	6
77	Synthesis, in vitro and in vivo studies, and molecular modeling of N-alkylated dextromethorphan derivatives as non-competitive inhibitors of $1\pm3\hat{1}^24$ nicotinic acetylcholine receptor. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6846-6856.	3.0	6
78	Computational Analysis of Chlorophyll Structure and UV-Vis Spectra: A Student Research Project on the Spectroscopy of Natural Complexes. <i>Spectroscopy Letters</i> , 2014, 47, 147-152.	1.0	18
79	Structural studies, homology modeling and molecular docking of novel non-competitive antagonists of GluK1/GluK2 receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 787-795.	3.0	14
80	Synthesis and molecular docking of indole and carbazole derivatives with potential pharmacological activity. <i>Heterocyclic Communications</i> , 2014, 20, 103-109.	1.2	2
81	Synthesis, central nervous system activity, and structure-activity relationship of 1-aryl-6-benzyl-7-hydroxy-2,3-dihydroimidazo[1,2-a]pyrimidine-5(1H)-ones. <i>Medicinal Chemistry Research</i> , 2014, 23, 4221-4237.	2.4	7
82	Investigation of novel ropinirole analogues: synthesis, pharmacological evaluation and computational analysis of dopamine D2 receptor functionalized congeners and homobivalent ligands. <i>MedChemComm</i> , 2014, 5, 891-898.	3.4	23
83	Application of BRET for Studying G Protein-Coupled Receptors. <i>Mini-Reviews in Medicinal Chemistry</i> , 2014, 14, 411-425.	2.4	19
84	In Vitro Screening of Some Heterocyclic Compounds Against Human ABHD6 and ABHD12 Hydrolases. <i>Letters in Drug Design and Discovery</i> , 2014, 11, 944-952.	0.7	2
85	Modeling the Active Conformation of Human $\hat{1}$ Opioid Receptor. <i>Letters in Drug Design and Discovery</i> , 2014, 11, 1053-1061.	0.7	3
86	Synthesis, Pharmacological Activity and Molecular Modeling of 1-Aryl-7-hydroxy-2,3-dihydroimidazo[1,2-a]pyrimidine-5(1H)-ones and their 6-Substituted Derivatives. <i>Medicinal Chemistry</i> , 2014, 10, 460-475.	1.5	8
87	Synthesis, Experimental and Computational Spectroscopic Studies, and Formation Thermodynamics of Diethyl [[2-(1-Aryl-4,5-dihydro-1H-imidazol-2-yl)hydrazinyl]methylene]propanedioates. <i>Letters in Organic Chemistry</i> , 2014, 11, 493-497.	0.5	0
88	Modeling Complexes of Transmembrane Proteins: Systematic Analysis of Protein-Protein Docking Tools. <i>Molecular Informatics</i> , 2013, 32, 717-733.	2.5	27
89	The pseudo-Michael reaction of 1-aryl-4,5-dihydro-1H-imidazol-2-amines with ethyl ethoxymethylenecyanoacetate. <i>Monatshefte für Chemie</i> , 2013, 144, 1171-1182.	1.8	3
90	Experimental and computational studies on the tautomerism of N-substituted 3-amino-5-oxo-4-phenyl-1H-pyrazolo-1-carboxamides with antibacterial activity. <i>Journal of Molecular Structure</i> , 2013, 1051, 188-196.	3.6	11

#	ARTICLE	IF	CITATIONS
91	Chiral 1,3,4-Oxadiazol-2-ones as Highly Selective FAAH Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8484-8496.	6.4	54
92	Structure-Based Molecular Modeling Approaches to GPCR Oligomerization. <i>Methods in Cell Biology</i> , 2013, 117, 91-104.	1.1	10
93	Simulating G Protein-Coupled Receptors in Native-Like Membranes. <i>Methods in Cell Biology</i> , 2013, 117, 63-90.	1.1	13
94	Rational design of the survivin/CDK4 complex by combining protein-protein docking and molecular dynamics simulations. <i>Journal of Molecular Modeling</i> , 2013, 19, 1507-1514.	1.8	8
95	Structural and Molecular Docking Studies of 4-Benzyl-3-[(1-methylpyrrol-1-yl)ethoxy]benzylamine. <i>Journal of Molecular Modeling</i> , 2013, 19, 313-328.	1.5	11
96	Fractal dimension as a measure of surface roughness of G protein-coupled receptors: implications for structure and function. <i>Journal of Molecular Modeling</i> , 2012, 18, 4465-4475.	1.8	17
97	Novel Non-Competitive Antagonists of Kainate GluK1/GluK2 Receptors. <i>Letters in Drug Design and Discovery</i> , 2012, 9, 891-898.	0.7	4
98	Novel Non-Competitive Antagonists of Kainate GluK1/GluK2 Receptors. <i>Letters in Drug Design and Discovery</i> , 2012, 9, 891-898.	0.7	3
99	Experimental and theoretical investigations on the keto-enol tautomerism of 4-substituted pyridin-2(1H)-ones. <i>Structure</i> , 2011, 994, 313-320.	3.6	14
100	Oligomerization of G Protein-Coupled Receptors: Computational Methods. <i>Current Medicinal Chemistry</i> , 2011, 18, 4588-4605.	2.4	35
101	Oligomerization of G Protein-Coupled Receptors: Biochemical and Biophysical Methods. <i>Current Medicinal Chemistry</i> , 2011, 18, 4606-4634.	2.4	53
102	Molecular Structure of Ionotropic Glutamate Receptors. <i>Current Medicinal Chemistry</i> , 2010, 17, 2608-2635.	2.4	29
103	Structure-based virtual screening for novel inhibitors of Japanese encephalitis virus NS3 helicase/nucleoside triphosphatase. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 58, 91-101.	2.7	9
104	Modeling of Glutamate GluR6 Receptor and Its Interactions with Novel Noncompetitive Antagonists. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 1094-1104.	5.4	14
105	Molecular structure and infrared spectra of the monomeric 3-(methoxy)-1,2-benzisothiazole 1,1-dioxide (methyl pseudosaccharyl ether). <i>Journal of Molecular Structure</i> , 2008, 876, 77-85.	3.6	22
106	Theoretical Studies on the Structure and Symmetry of the Transmembrane Region of Glutamatergic GluR5 Receptor. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3765-3776.	6.4	11
107	Crystal Structure of 1-(4-Chlorophenyl)-5(1H)-oxo-2,3-dihydroimidazo[1,2-a]-pyrimidine-6-carbonitrile. <i>Analytical Sciences: X-ray Structure Analysis Online</i> , 2008, 24, X119-X120.	0.1	0
108	EMCA and DEEM as Michael Reagents Used in Organic Synthesis. <i>Current Organic Chemistry</i> , 2005, 9, 1237-1259.	1.6	11

#	ARTICLE	IF	CITATIONS
109	Non-peptide Opioid Receptor Ligands - Recent Advances. Part I - Agonists. <i>Frontiers in Drug Design and Discovery</i> , 2004, 1, 477-500.	0.3	1
110	Non-peptide Opioid Receptor Ligands - Recent Advances. Part I - Agonists. <i>Current Medicinal Chemistry</i> , 2002, 9, 1567-1589.	2.4	30
111	Non-peptide Opioid Receptor Ligands - Recent Advances. Part II - Antagonists. <i>Current Medicinal Chemistry</i> , 2002, 9, 1591-1603.	2.4	29